CA3249500A1 - USES OF FARNESOID X RECEPTOR AGONISTS - Google Patents

USES OF FARNESOID X RECEPTOR AGONISTS

Info

Publication number
CA3249500A1
CA3249500A1 CA3249500A CA3249500A CA3249500A1 CA 3249500 A1 CA3249500 A1 CA 3249500A1 CA 3249500 A CA3249500 A CA 3249500A CA 3249500 A CA3249500 A CA 3249500A CA 3249500 A1 CA3249500 A1 CA 3249500A1
Authority
CA
Canada
Prior art keywords
patient
compound
score
pharmaceutically acceptable
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3249500A
Other languages
English (en)
French (fr)
Inventor
Thomas CAPOZZA
Original Assignee
Alfasigma SpA
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfasigma SpA, Intercept Pharmaceuticals Inc filed Critical Alfasigma SpA
Publication of CA3249500A1 publication Critical patent/CA3249500A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3249500A 2022-04-21 2023-04-21 USES OF FARNESOID X RECEPTOR AGONISTS Pending CA3249500A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263333287P 2022-04-21 2022-04-21
US63/333,287 2022-04-21
US202263381752P 2022-10-31 2022-10-31
US63/381,752 2022-10-31
PCT/US2023/019448 WO2023205447A2 (en) 2022-04-21 2023-04-21 Uses of farnesoid x receptor agonists

Publications (1)

Publication Number Publication Date
CA3249500A1 true CA3249500A1 (en) 2023-10-26

Family

ID=88420596

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3249500A Pending CA3249500A1 (en) 2022-04-21 2023-04-21 USES OF FARNESOID X RECEPTOR AGONISTS

Country Status (10)

Country Link
US (1) US20250288600A1 (enExample)
EP (1) EP4511012A2 (enExample)
JP (1) JP2025513289A (enExample)
KR (1) KR20250006156A (enExample)
CN (1) CN119136794A (enExample)
AU (1) AU2023257308A1 (enExample)
CA (1) CA3249500A1 (enExample)
IL (1) IL315941A (enExample)
MX (1) MX2024012966A (enExample)
WO (1) WO2023205447A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4611888A1 (en) * 2022-10-31 2025-09-10 Intercept Pharmaceuticals, Inc. Uses of farnesoid x receptor agonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3777863A1 (en) * 2014-09-12 2021-02-17 Tobira Therapeutics, Inc. Cenicriviroc combination therapy for the treatment of fibrosis
PE20180690A1 (es) * 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
EP3426348B1 (en) * 2016-03-11 2021-05-05 Intercept Pharmaceuticals, Inc. 3-desoxy derivative and pharmaceutical compositions thereof
JP7224307B2 (ja) * 2017-06-23 2023-02-17 インターセプト ファーマシューティカルズ， インコーポレイテッド 胆汁酸誘導体の調製のための方法及び中間体

Also Published As

Publication number Publication date
KR20250006156A (ko) 2025-01-10
CN119136794A (zh) 2024-12-13
WO2023205447A2 (en) 2023-10-26
IL315941A (en) 2024-11-01
US20250288600A1 (en) 2025-09-18
JP2025513289A (ja) 2025-04-24
EP4511012A2 (en) 2025-02-26
MX2024012966A (es) 2024-11-08
WO2023205447A3 (en) 2024-04-04
AU2023257308A1 (en) 2024-10-10

Similar Documents

Publication Publication Date Title
Trauner et al. The nonsteroidal farnesoid X receptor agonist cilofexor (GS‐9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis
Rautiainen et al. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three‐year randomized trial
Krones et al. NorUrsodeoxycholic acid ameliorates cholemic nephropathy in bile duct ligated mice
Wong et al. Hypophysitis presented as inflammatory pseudotumor in immunoglobulin G4-related systemic disease
Trauner et al. Safety and sustained efficacy of the farnesoid X receptor (FXR) agonist cilofexor over a 96-week open-label extension in patients with PSC
JP2021063088A (ja) 非アルコール性脂肪肝疾患および／またはリポジストロフィーの処置のための方法
JP2020147585A (ja) 肝臓の疾患を治療するためのオメガ３脂肪酸とｓｇｌｔ−２阻害薬との併用剤
Debédat et al. Impact of bariatric surgery on type 2 diabetes: contribution of inflammation and gut microbiome?
Felicetti et al. Cancer survivors: an expanding population with an increased cardiometabolic risk
US20220143003A1 (en) Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
Kotsopoulos et al. Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation
US20250288600A1 (en) Uses of farnesoid x receptor agonists
Schmitt et al. Complement factor C5 deficiency significantly delays the progression of biliary fibrosis in bile duct-ligated mice
González et al. Saturated fat ingestion stimulates proatherogenic inflammation in polycystic ovary syndrome
Uchiyama et al. Open-label, randomized, controlled, crossover trial on the effect of dapagliflozin in patients with ADPKD receiving tolvaptan
Li et al. Effects of cisplatin and letrozole on surgically induced endometriosis and comparison of the two medications in a rat model
EP4611888A1 (en) Uses of farnesoid x receptor agonists
Oleszczuk et al. Regenerative capacity differs between micro-and macrovesicular hepatic steatosis
CN115605198A (zh) 脂肪性肝病的治疗药
US20230000832A1 (en) Use of neuropilin antagonists for the treatment of endometriosis
US20210349103A1 (en) Metabolic biomarkers of nafld/nash and related disease phenotypes and methods of using same
Pagán et al. Budesonide combined with ursodeoxycholic acid in primary biliary cirrhosis with advanced liver damage
Lee et al. Changes in Insulin-like Growth Factor-1 Level in Patients with Sepsis and Septic Shock
Şenyuva et al. The effects of progesterone on the healing of obstetric anal sphincter damage in female rats
Schuppe et al. Andrology

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20241017

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20241115

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241115

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241115

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20241120

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250411

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250411

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE

Effective date: 20260313

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260313

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260318

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260323

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260323